People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $270.2M | 2013 |
| Cambridge Crops, Inc. | — | Other | Series C | $85.7M | $618.2M | 2019 |
Livio Valenti at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Livio Valenti on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 2 | 10 |
| Peter Kolchinsky | 1 | 8 |
| Aaron Sandoski | 1 | 7 |
| Laura Witt | 1 | 5 |
| Lucas Mann | 1 | 5 |
| Rachel Sha | 1 | 4 |
| Purnanand Sarma | 1 | 3 |
| Michael Schrader | 1 | 3 |
| James Connolly | 1 | 3 |
| Mark Tracy | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Mario Barro | 1 | 3 |
| Johannes Fruehauf | 1 | 2 |
| Jonathan M. Kluge | 1 | 1 |
| Lynda M. Tussey | 1 | 1 |
| Ted Hibben | 1 | 1 |
| Scott Sonnemaker | 1 | 1 |
| Adam Behrens | 1 | 1 |
| Laith Abu-Taleb | 1 | 1 |
| Mark Doiron | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.